Adaptive Biotechnologies Corp (ADPT) Q4 2024 Earnings Report Preview: What To Look For

Author's Avatar
Feb 10, 2025
Article's Main Image

Adaptive Biotechnologies Corp (ADPT, Financial) is set to release its Q4 2024 earnings on Feb 11, 2025. The consensus estimate for Q4 2024 revenue is $46.03 million, and the earnings are expected to come in at -$0.26 per share. The full year 2024's revenue is expected to be $177.67 million and the earnings are expected to be -$1.15 per share. More detailed estimate data can be found on the Forecast page.

Adaptive Biotechnologies Corp (ADPT, Financial) Estimates Trends

Revenue estimates for Adaptive Biotechnologies Corp (ADPT) have increased from $174.16 million to $177.67 million for the full year 2024 and increased from $208.39 million to $210.66 million for 2025 over the past 90 days. Earnings estimates for Adaptive Biotechnologies Corp (ADPT) have increased from -$1.21 per share to -$1.15 per share for the full year 2024 and increased from -$1.01 per share to -$0.99 per share for 2025 over the past 90 days.

Adaptive Biotechnologies Corp (ADPT, Financial) Reported History

In the previous quarter of 2024-09-30, Adaptive Biotechnologies Corp's (ADPT) actual revenue was $46.44 million, which beat analysts' revenue expectations of $40.21 million by 15.49%. Adaptive Biotechnologies Corp's (ADPT) actual earnings were -$0.22 per share, which beat analysts' earnings expectations of -$0.29 per share by 24.91%. After releasing the results, Adaptive Biotechnologies Corp (ADPT) was up by 3.37% in one day.

Adaptive Biotechnologies Corp (ADPT, Financial) 12 Month Price Targets

Based on the one-year price targets offered by 5 analysts, the average target price for Adaptive Biotechnologies Corp (ADPT) is $8.10 with a high estimate of $10.00 and a low estimate of $7.00. The average target implies an upside of 3.32% from the current price of $7.84.

Based on GuruFocus estimates, the estimated GF Value for Adaptive Biotechnologies Corp (ADPT, Financial) in one year is $8.47, suggesting an upside of 8.04% from the current price of $7.84.

Based on the consensus recommendation from 8 brokerage firms, Adaptive Biotechnologies Corp's (ADPT, Financial) average brokerage recommendation is currently 2.0, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.